Distinct Mechanisms Mediate the Initial and Sustained Phases of Integrin-mediated Activation of the Raf/MEK/Mitogen-activated Protein Kinase Cascade by Howe, Alan K. & Juliano, Rudy L.
Distinct Mechanisms Mediate the Initial and Sustained Phases of
Integrin-mediated Activation of the Raf/MEK/Mitogen-activated
Protein Kinase Cascade*
(Received for publication, April 9, 1998, and in revised form, July 24, 1998)
Alan K. Howe‡ and Rudy L. Juliano§
From the Department of Pharmacology and The Lineberger Comprehensive Cancer Center, University of North Carolina
at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599-7365
Integrin-mediated adhesion to the extracellular ma-
trix activates the canonical mitogen-activated protein
kinase cascade, although the exact mechanism is not
fully resolved. We show that integrin-mediated activa-
tion of Raf-1, an upstream regulator of mitogen-acti-
vated protein kinase, occurs in two phases. Efficient
early activation of Raf required Raf-Ras interaction but
was not affected by protein kinase C (PKC) inhibitors,
while a lower, sustained level of activity was independ-
ent of Raf-Ras interaction but was reduced by PKC in-
hibitors. The combination of PKC inhibition and lack of
Ras binding completely blocked integrin-mediated Raf
activity. The activity of a membrane-bound Raf mutant
that is deficient in Ras binding (Raf-R89L-CAAX) was
also regulated by adhesion. Raf-R89L-CAAX activity was
low in nonadherent cells, was rapidly stimulated to
wild-type levels by cell adhesion, and remained at
nearly maximal levels longer than wild-type activity.
The activation of wild-type and mutant Raf proteins was
ablated by cytochalasin D, demonstrating that cytoskel-
etal organization is required for activation of Raf, even
when targeted to the membrane. These data suggest
distinct initial and sustained phases of integrin-medi-
ated Raf activation that require Raf membrane localiza-
tion and possibly PKC activity, respectively, and that
integrin-mediated adhesion may regulate a cytoskele-
ton-associated factor(s) responsible for Raf activation.
It has been known for some time that a cell’s interaction with
the extracellular matrix (ECM)1 can have profound effects on
cell division, differentiation, and survival. Interactions be-
tween cells and the ECM are mediated predominantly by het-
erodimeric transmembrane proteins known as integrins (1, 2).
It has become increasingly clear that integrins not only medi-
ate the physical attachment of cells to ECM but also generate
a variety of signals that communicate the status of this attach-
ment to the interior of the cell (3–5). These signals can regulate
a variety of cellular functions, including cell morphology
and motility, apoptosis, differentiation, and cell growth and
division (3, 6).
Among the signals generated by integrin-mediated cell ad-
hesion is activation of the canonical MAPK cascade (7–12). The
mechanism of activation of this cascade in response to mitogens
such as peptide growth factors has been delineated in great
detail (13). It involves dimerization and autophosphorylation of
the growth factor receptor tyrosine kinase (RTK), recruitment
of an adaptor protein-guanine nucleotide exchange factor com-
plex (e.g. GRB2-mSOS), and GTP loading and activation of
small GTPase Ras (14). Ras binds the serine/threonine kinase
Raf (15) and recruits it to the membrane, where it is activated
by a complex and as yet unresolved mechanism (16). Once
activated, Raf phosphorylates and activates MEK (MAPK/ex-
tracellular signal-regulated kinase), which in turn phosphoryl-
ates and activates MAPK.
While integrin-mediated activation of the MAPK cascade has
been reported by several groups, the mechanism(s) through
which this occurs is currently somewhat controversial. The
events immediately upstream of MAPK seem clear; both Raf-1
and MEK are activated by integrin-mediated adhesion (7, 17),
and MEK activity is required for integrin-mediated MAPK
activation (7). However, the events upstream of Raf are less
clear. On one hand, integrin-mediated Raf activation may occur
through a pathway that is essentially a recapitulation of the
canonical growth factor-activated pathway. Thus, integrin en-
gagement induces autophosphosphorylation of the focal adhe-
sion kinase pp125FAK, which may serve as a surrogate RTK
domain and point of purchase for adaptor protein exchange
factor complexes (10, 18). In this model, integrin-mediated
activation of the Raf/MEK/MAPK cascade is dependent on both
pp125FAK and Ras. Indeed, several groups have demonstrated
that expression of dominant negative Ras (RasN17) can inhibit
integrin-mediated MAPK activation (17–22). However, our lab-
oratory and others have demonstrated that integrin-mediated
MAPK activation can occur independently of pp125FAK (21, 23).
Furthermore, work from our laboratory has provided evidence
for a Ras-independent component of integrin-mediated MAPK
activation (7). Specifically, a level of expression of RasN17 suf-
ficient to block signaling from a constitutively active mSOS
exchange factor was unable to inhibit integrin-mediated acti-
vation of MEK (7). Also, expression of an amino-terminal frag-
ment of Raf-1 (amino acids 23–284) containing the Ras binding
site (24) blocked the activation of the MAPK pathway by onco-
genic Ras (RasV12) but not by integrin-mediated cell adhesion
(7).
In this report, we focus on the mechanism of activation of
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Raf-1 by integrin-mediated cell adhesion. Our results show
that integrin-mediated activation of Raf-1 seems to comprise
two phases: an early phase that is enhanced or optimized by
membrane localization and is independent of protein kinase C
(PKC) activity and a later, sustained phase that is independent
of Ras-Raf association but is blocked by inhibitors of PKC.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Transfections—NIH3T3 fibroblasts were
routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum. Plasmids encoding various myc-
tagged Raf-1 alleles (pEFHm-Raf-WT, -Raf-R89L, -Raf-R89L-CAAX,
and -Raf-K375M) were a kind gift from Drs. Richard Marais and Chris-
topher Marshall (25). A plasmid encoding oncogenic Ras (pZIP-RasV12)
was originally obtained from Dr. Channing Der. For transfections, cells
were seeded at 3 3 105 cells/well in six-well (35-mm diameter) plates
(Falcon Corp.) or 1 3 106 cells/60-mm dish and incubated overnight at
37 °C. Complexes containing 8 ml of LipofectAMINE (Life Technologies,
Inc.) and 2 mg of plasmid DNA (unless otherwise noted) were formed
and applied to cells according to the manufacturer’s instructions. For
transfection of cells in 60-mm dishes, 25 ml of LipofectAMINE and 5 mg
of plasmid were used. Cells were grown to confluence (usually 24–36 h
after transfection), refed with serum-free DMEM, and harvested for
specific applications as described below.
Adhesion of Cells to Fibronectin-coated Plates—Plastic Petri dishes
(Corning) were coated in an overnight incubation at room temperature
with 25 mg/ml human fibronectin (Fn; Collaborative Biochemicals) or 5
mg/ml poly-L-lysine (Sigma) in phosphate-buffered saline (PBS) (2 ml/
60-mm dish; 5 ml/100-mm dish). Plates were washed once with PBS and
once with sterile, deionized water before use. Serum-starved cells were
trypsinized, resuspended in DMEM containing 2% bovine serum albu-
min (lipid- and globulin-free; Sigma), and 2 mg/ml soybean trypsin
inhibitor (Life Technologies), collected by brief centrifugation, and
washed once with DMEM, 2% BSA. Cells were incubated in suspension
in DMEM, 2% BSA at 37OC with gentle rotation for 1 h and then
transferred to coated plates for the indicated times or kept in suspen-
sion for an equivalent time. Cells were then harvested for the appro-
priate analysis as described in the figure legends and below. In some
instances, rather than being harvested by trypsinization, serum-
starved cells were stimulated with TPA (100 nM, 10 min) as controls.
Note that cells were replated onto Fn-coated plates at a density no
greater than 30% confluence to minimize cell-cell contact.
Pharmacological Reagents—PKC activity was inhibited using either
calphostin C or bisindolylmaleimide (BIM) (LC Laboratories). Calphos-
tin C was activated by exposure to room light for 30 min at room
temperature before use. Cells were incubated in serum-free DMEM
containing the indicated amounts of the inhibitors or in 0.1% (v/v)
Me2SO as a control, for either 12–16 h (long term treatment) or 1 h
(short term treatment) before harvesting. For long term treatments,
inhibitors or Me2SO were present in all media (except for trypsin)
throughout a given experiment. For short term treatments, inhibitor or
Me2SO was added to the cells at the beginning of their incubation in
suspension. To prevent actin filament assembly, cytochalasin D was
added at a concentration of 2 mM to cells in suspension 45 min before
replating.
Preparation of Cell Extracts and Western Blotting—Cells were
washed twice with ice-cold PBS and then lysed in an appropriate
volume of radioimmunoprecipitation assay buffer (25 mM Tris, pH 7.4,
137 mM NaCl, 1.0% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
10% glycerol) or Triton lysis buffer (25 mM Tris, pH 8.0, 137 mM NaCl,
1.0% Triton X-100, 10% glycerol) containing protease and phosphatase
inhibitors (PMSF/aprotinin/pepstatin and sodium orthovanadate/so-
dium fluoride, respectively). Dishes were scraped, and lysates were
transferred to microcentrifuge tubes, which were then vortexed and
incubated on ice for 10 min. Insoluble debris was removed by centrifu-
gation at 14,000 rpm for 10 min at 4 OC, and the clarified lysates were
used for determination of protein concentration and subsequent steps.
For Western blot analysis, 10–20 mg of cell extract or one-tenth the total
volume of an immunoprecipitation complex were mixed with the appro-
priate volume of 43 Laemmli sample buffer, boiled for 5 min, separated
by SDS-PAGE (7.5% acrylamide for Raf, 10% for MEK and MAPK, 12%
for Ras), and transferred to nitrocellulose. Membranes were blocked in
PBS containing 5% (w/v) nonfat dry milk and 0.1% (v/v) Tween 20 and
incubated with primary antibodies against Raf-1 (sc-133 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) or R19120 (Transduction Labora-
tories); 1:1000), MEK1 and -2 (M17030 (Transduction Laboratories),
1:1000), Ras (Y13–259 (Calbiochem), 1:250), or MAPK (sc-154 (Santa
Cruz Biotechnology), 1:1000) for 1 h at room temperature or overnight
at 4 OC. After extensive washing, membranes were incubated with
appropriate horseradish peroxidase-conjugated secondary antibodies
(goat anti-mouse (1:2000) or goat anti-rabbit (1:5000) Santa Cruz Biotech-
nology) and washed again, and immunoreactive bands were visualized
using enhanced chemiluminescence (Amersham Pharmacia Biotech).
Immunoprecipitations and Kinase Assays—Ras-Raf co-immunopre-
cipitations were performed essentially as described (26), using 2.5–3.0
mg of cellular protein for each experimental point. For kinase assays,
cell extracts (200–800 mg) were incubated with one of the antibodies
described above (or 9E10 (Berkeley Antibody Company) for myc-tagged
Raf proteins), using 1 mg of antibody for every 100 mg of cellular protein,
for 2 h at 4 OC, and then with 30 ml of protein A/G-agarose for an
additional 30 min. MAPK immunocomplexes were washed twice with
radioimmunoprecipitation assay buffer; once with 100 mM Tris, pH 8.6,
500 mM LiCl; and once with kinase buffer (25 mM HEPES 7.4, 10 mM
MgCl2, 10 mM MnCl2, 1 mM dithiothreitol). MEK immunocomplexes
were washed three times with Triton lysis buffer and once in kinase
buffer. myc-tagged Raf immunocomplexes were washed three times
with Triton lysis buffer and twice with Raf kinase buffer (25 mM
HEPES 7.4, 10 mM MgCl2, 100 mM NaCl, 1 mM dithiothreitol, 5 mM
ATP). Immunocomplexes were then incubated in 40 ml of kinase buffer
containing 20 mCi [g-32P]ATP (3000 Ci/mmol; NEN Life Science Prod-
ucts) and the appropriate substrate (5 mg of myelin basic protein for
MAPK assays, 2 mg of kinase-dead MAPK for MEK assays, or 0.5 mg of
kinase-dead MEK for Raf assays) for 30 min at room temperature. In
some instances, Raf activity was assayed in a linked assay containing
0.1 mg of inactive MEK plus 1 mg of kinase-dead MAPK. Reactions were
terminated by the addition of 40 ml of 23 Laemmli sample buffer and
boiling for 2–5 min. Reaction products were separated by SDS-PAGE
and visualized from the stained, dried gel either by autoradiography or
by PhosphorImager analysis (Molecular Dynamics, Inc., Sunnyvale,
CA). Quantitation of substrate phosphorylation was performed using
ImageQuant software (Molecular Dynamics).
RESULTS
Integrin-mediated Adhesion Activates a Mutant of Raf Defi-
cient in Ras Binding—Although Ras plays an important role in
the activation of Raf by growth factors, its role in integrin-
mediated signaling is a point of contention. It is firmly estab-
lished that Ras and Raf form a stable complex and that this
direct interaction is required for Ras-mediated Raf activation
(15, 16). However, preliminary co-immunoprecipitation exper-
iments failed to demonstrate a significant increase in Raf-Ras
association upon integrin-mediated adhesion.2 To more directly
address the question of whether interaction with Ras is re-
quired for integrin-mediated activation of Raf-1, cells were
transiently transfected with plasmids encoding either wild-
type Raf (Raf-WT) or a mutant allele containing an arginine to
leucine substitution at position 89, within the Ras binding
domain (Raf-R89L) (25). This single point mutation eliminates
Raf interaction with Ras and renders Raf refractory to activa-
tion by Ras (27). The inability of Ras to activate the R89L
mutant was confirmed by co-transfection of Raf plasmids with
increasing amounts of a plasmid encoding the activated, onco-
genic Ras allele RasV12 (Fig. 1A). Immunoprecipitation of the
transfected, epitope-tagged kinase showed that the wild-type
Raf was robustly activated by oncogenic Ras, while Raf-R89L,
as expected, was not significantly activated by Ras. The activ-
ity of these Raf alleles in response to integrin-mediated adhe-
sion was then measured (Fig. 1B). We found that adhesion to
fibronectin could activate both the WT and R89L forms of Raf,
although the level of activation of the R89L mutant was lower
than that of Raf-WT (Fig. 1, B and D). To confirm that the level
of activation seen for Raf-R89L was indeed significant, the
activity of a catalytically inactive mutant of Raf (K375M) was
determined in nonadherent and Fn-attached cells and used as
a measure of zero activation (Fig. 1D). The results of several
(n $ 5) experiments were averaged (Fig. 1D), which showed
2 A. Howe and R. Juliano, unpublished observations.
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that, after 15 min of adhesion, the activation of Raf-R89L was
significant but 4–5-fold lower than the level of activation of
wild-type Raf. It should be noted that activation of Raf clearly
involves specific adhesion to Fn, mediated primarily by inte-
grins, because cells adhering to the nonspecific cationic poly-
mer poly-L-lysine do not activate Raf (data not shown). In
summary, these experiments demonstrate that significant ac-
tivation of Raf by integrin-mediated adhesion can occur in the
absence of direct Ras-Raf interaction but that this interaction
clearly enhances integrin-mediated Raf activation.
Integrin-mediated Adhesion Regulates Raf-R89L-CAAX Ac-
tivity—It is well established that localization of Raf-1 to the
plasma membrane is important for its activation (28) and that
one function of Ras is to mediate this localization (25, 29).
However, the nature of the membrane-associated machinery
responsible for Raf activation remains unclear (16). To examine
the importance of membrane localization in integrin-mediated
Raf activation and to determine if the function of Ras could be
supplanted by targeting Raf to the membrane, we used a ver-
sion of the R89L mutant that carries at its C-terminus a 20-
amino acid sequence known as a CAAX box (Raf-R89L-CAAX).
This sequence directs prenylation and membrane localization
of Raf and, in adherent cells, results in a high constitutive level
of Raf-R89L-CAAX activity, despite its inability to bind Ras
(25, 28). Cells were transiently transfected with Raf-WT or
Raf-R89L-CAAX, serum-starved, harvested, and either kept in
suspension or plated on fibronectin for 15 min and analyzed by
an immunoprecipitation kinase assay (Fig. 1C). Interestingly,
Raf-R89L-CAAX activity, which is normally high in attached
cells, was low in cells in suspension but increased upon cellular
attachment to fibronectin, and the level of this activation was
similar to that for Raf-WT (Fig. 1, C and D). Subcellular frac-
tionation, membrane isolation, and Western blot analysis indi-
cated that the low level of activity of Raf-R89L-CAAX in non-
adherent cells was not due to a loss or reduction of membrane
localization of the protein during suspension culture conditions
(data not shown). These data suggest that integrin-mediated
cell adhesion can efficiently activate Raf-1 when Raf is able to
localize to the cell membrane, as with Raf-WT or Raf-R89L-
CAAX, while significant, but reduced, activation can occur even
when membrane localization is compromised, as with Raf-R89L.
Furthermore, the lack of Raf-R89L-CAAX activity in nonadher-
ent cells suggests that cell adhesion may regulate the membrane-
associated machinery responsible for Raf activation after its
translocation to the membrane.
Integrin-mediated Activation of Wild-type and Mutant Raf
Alleles Requires Actin Cytoskeletal Organization—The regula-
tion by adhesion of Raf-R89L-CAAX suggests that membrane-
proximal regulators of Raf activity are sensitive to integrin
function. One of the most important functions of integrins is to
anchor actin filaments to the membrane at points of contact
with the ECM, thereby supporting the assembly of stress fibers
and organization of the actin cytoskeleton. To examine whether
cytoskeleton assembly is important for integrin-mediated Raf
activation, we treated cells with cytochalasin D (cytoD), a
widely used and well characterized inhibitor of actin filament
formation. Previous reports have established that disruption of
the actin cytoskeleton, through treatment with cytoD or expres-
sion of dominant negative Rho, inhibits integrin-mediated MAPK
FIG. 1. Integrin-mediated activation of wild-type and mutant
Raf proteins. NIH3T3 cells were transiently transfected with plas-
mids encoding epitope-tagged Raf-WT, a point mutant deficient in Ras-
binding (R89L), a membrane-associated form of this mutant (R89L-
CAAX), or a catalytically inactive mutant (K375M). A, cells were co-
transfected with plasmids encoding WT or R89L Raf and increasing
amounts (1, 3, and 9 mg) of a plasmid encoding oncogenic Ras (RasV12).
After reaching confluence, cells were serum-starved overnight and har-
vested, and the transfected Raf proteins were immunoprecipitated with
an antibody (9E10) against the myc epitope tag. The activity of the
immunoprecipitated proteins was assayed as described under “Experi-
mental Procedures,” using kinase-dead MEK as a substrate. B and C,
cells transfected with the indicated Raf constructs were grown to con-
fluence, serum-starved, cultured in suspension, and either replated
onto Fn-coated dishes (Fn) or maintained in suspension (Susp.) for 15
min. Tagged proteins were immunoprecipitated using the 9E10 anti-
myc tag antibody and analyzed by either in vitro kinase assay (top parts
of B and C) or by Western blotting with anti-Raf antibody (bottom
parts). D, relative integrin-mediated activation of Raf proteins. The fold
activation (i.e. the ratio of activity after plating to the activity in
suspension) was determined for WT and mutant Raf proteins. For each
experiment, these values were normalized to the WT value, which was
given an arbitrary unit of 1. The error bars indicate the S.D. (n 5 5, 7,
6, and 3 for WT, R89L, R89L-CAAX, and K375M, respectively).
Two Distinct Phases in Integrin-mediated Raf Activation27270
activation (8, 9, 11, 30). In agreement with this, cytoD inhibited
integrin-mediated activation of Raf-WT, as well as Raf-R89L and,
interestingly, Raf-R89L-CAAX (Fig. 2). This demonstrates that
cytoskeletal organization is required for integrin-mediated Raf
activation, even for a membrane-targeted form of Raf.
Time Course of Integrin-mediated Activation of Wild-type
and Mutant Raf Alleles—Compared with the response to most
soluble mitogens, activation of the MAPK cascade by integrin-
mediated adhesion is of lower magnitude and longer duration
(3). In NIH3T3 cells, integrin-mediated MAPK activity peaks
10–15 min after adhesion and returns to basal levels by 2 h (7,
8). Important aspects of the relative activation of Raf-WT and
the R89L and R89L-CAAX mutants may not be fully realized
by a single time point. Therefore, we determined the time
course of integrin-mediated activity of Raf-WT, Raf-R89L, and
Raf-R89L-CAAX. As described previously for MAPK, integrin-
mediated Raf-WT activity peaked at 10–20 min after adhesion
to fibronectin and slowly returned to near basal levels by 2 h
(Fig. 3). As described above in Fig. 1, the activation of Raf-R89L
at early time points after attachment (i.e. 10–15 min) is signif-
icantly lower than Raf-WT. However, the level of activity of
Raf-R89L throughout the later time points (i.e. 40–120 min) is
almost indistinguishable from WT levels (Fig. 3). Specifically,
Raf-R89L exhibits the same level of activity as Raf-WT at 40
min after cellular adhesion to fibronectin, and the rate at which
this activity returns to basal level (i.e. the level present in
nonadherent cells) parallels the rate of decay of WT activity. It
is important to note that, for these experiments, transfections
were performed on cells in six-well dishes, and upon trypsiniza-
tion, all cells from a given plate were pooled, replated on Fn,
and then harvested at different times. Using a pooled cell
population for the time course experiments eliminates varia-
bility in levels of Raf expression between time points, a point
that was confirmed by Western blot analysis of the immuno-
precipitated Raf isoforms (Fig. 3A, bottom panel).
In contrast to the allele containing only the R89L point
mutation, the membrane-targeted Raf-R89L-CAAX was acti-
vated as efficiently as Raf-WT at early time points after cell
adhesion (Fig. 1, C and D; Fig. 2). However, unlike both
Raf-WT and the R89L point mutant, the activity of the R89L-
CAAX mutant did not return to basal levels by 2 h but rather
persisted at greater than 90% of maximum levels for the length
of the experiment. Although a detailed, extended time course of
adhesion-mediated Raf-R89L-CAAX activity has not been
done, preliminary experiments suggest that the activity re-
turns to base line within 8 h after adhesion (data not shown).
These results demonstrate that constitutive localization of Raf
to the cell membrane allows for a significantly prolonged acti-
vation of Raf upon cellular adhesion to fibronectin.
Inhibitors of PKC Activity Block the Sustained Phase but Not
the Initial Phase of Integrin-mediated Activation of the MAPK
Cascade—The results above suggested that integrin-mediated
adhesion might regulate factors involved in the activation of
membrane-localized Raf. In an attempt to determine what
these factors might be, we began to investigate the importance
of known positive regulators of Raf activity. Members of the
PKC family of kinases are well known for their ability to
activate MAPK through Raf (31–35). To evaluate whether PKC
FIG. 2. Disruption of actin cytoskeleton assembly blocks inte-
grin-mediated activation of WT and mutant Raf proteins. Cells
were transfected with the indicated plasmids and cultured as described
for Fig. 1. Me2SO (0.02% (v/v); white bars) or 2 mM cytochalasin D (gray
bars) was added to cells while in suspension, 45 min prior to replating.
Cells were replated onto Fn-coated dishes or maintained in suspension
for an additional 15 min. In each case, the cells were fully adherent;
however, the cytochalasin D-treated cells were noticeably less spread
than the control cells. The activity of the epitope-tagged kinases was
assayed by an immunoprecipitation kinase assay using the 9E10 anti-
body, and the fold activation by adhesion to Fn was calculated. Values
were normalized to the fold activation of Raf-WT in control (Me2SO)-
treated cells. The error bars indicate S.D. (n 5 3 for all points).
FIG. 3. Time course of integrin-mediated activation of WT,
R89L, and R89L-CAAX Raf. A, cells were transfected with the indi-
cated plasmids, cultured briefly in suspension, and plated onto Fn-
coated dishes as described for Fig. 1. Cells were harvested at the
indicated times, and Raf activity was determined by an immunoprecipi-
tation kinase assay. For each transfection, a portion (1⁄5) of each immu-
noprecipitate was removed prior to kinase assay and analyzed by SDS-
PAGE and Western blotting with anti-Raf antibody. A typical example,
demonstrating equal amounts of immunoprecipitated Raf-WT, is shown
(bottom part). B, average fold activation and S.D. values from four
independent transfections (Raf-WT (open squares), Raf-R89L (filled
circles), and Raf-R89L-CAAX (filled triangles)).
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activity was required for integrin-mediated activation of the
Raf/MEK/MAPK cascade, we assayed integrin-mediated
MAPK activity in the absence and presence of the PKC inhib-
itor BIM. Cells were treated with the indicated concentrations
of BIM overnight, treated with phorbol ester for 10 min or
replated onto fibronectin- or poly-L-lysine-coated plates for 15
min, and then harvested for MAPK immunoprecipitation ki-
nase assay. While the activation of MAPK elicited by 100 nM
TPA, a PKC agonist, was almost completely inhibited by 2 mM
BIM (Fig. 4A, top), adhesion-mediated MAPK activation was
still apparent in the presence of up to 10 mM BIM (Fig. 4, A
(bottom) and B). A similar pattern was seen using another PKC
inhibitor, calphostin C (data not shown), and similar results
were obtained for integrin-mediated activation of both MEK
(data not shown) and Raf (see below). Although the level of
MAPK activity induced by adhesion to Fn decreased slightly
with increasing amounts of BIM, the background level, i.e. the
activity in nonadherent cells, also decreased. Therefore, the
-fold activation, i.e. the ratio of activity in Fn-adherent and
-nonadherent cells, was not significantly different in the ab-
sence or presence of BIM. Thus, at early time points, the
inhibition of PKC does not affect the ability of integrin-medi-
ated adhesion to activate the MAPK pathway.
To determine whether the sensitivity to PKC inhibitors
changed over the course of integrin-mediated activation of the
MAPK cascade, the time course of Raf activity in the absence or
presence of BIM was assayed. Cells were incubated with BIM
either overnight or for 1 h before replating. Under both treat-
ment conditions, both treated and untreated cells exhibited
peak integrin-mediated Raf activity between 10 and 15 min
after plating (Fig. 4, C and D). However, in cells treated with
BIM, integrin-mediated Raf activity dropped from peak to ba-
sal levels significantly faster than in untreated cells. Specifi-
cally, integrin-mediated Raf activity returned to base line be-
tween 30 and 40 min after plating in the presence of inhibitor,
while in the absence of inhibitor, the level of Raf activity within
this time period was still at 75–80% of peak activity, and took
longer than 60 min to return to base line. These data suggest
that PKC activity is not required for the early or initial phase of
integrin-mediated activation of the MAPK cascade, but it does
FIG. 4. Inhibition of PKC affects the sustained but not the
initial phase of integrin-mediated activation of the Raf/MAPK
pathway. A, confluent NIH3T3 cells were incubated overnight in se-
rum-free DMEM containing 0.1% (v/v) Me2SO (0) or the indicated
amounts of BIM and then either stimulated with 100 nM TPA (top) or
cultured briefly in suspension and then replated onto dishes coated
with poly-L-lysine (P) or Fn (bottom). Cells were harvested 10 min after
TPA stimulation or 15 min after plating, and MAPK activity was
measured by an immunoprecipitation kinase assay using myelin basic
protein (MBP) as a substrate. B, graphic representation of densitomet-
ric values obtained from A (bottom). C, cells were treated with 0.1% (v/v)
Me2SO (Control) or 2.5 mM BIM and cultured as described. Cells were
harvested at the indicated times, and Raf activity was measured by
immunoprecipitation and a linked kinase assay utilizing recombinant
wild-type MEK, kinase-dead MAPK (k2 MAPK), and [g-32P]ATP. D,
confluent cells were treated overnight with 0.1% (v/v) Me2SO (filled
squares) or 2.5 mM bisindolylmaleimide (filled triangles) before
trypsinization, suspension culture, and re-plating on Fn-coated plates.
Alternatively, cells were treated for 1 h, while in suspension, with
Me2SO (open squares) or BIM (open triangles) at the same concentra-
tions as above. Cells were extracted at the indicated times, and Raf
activity was assayed by an immunoprecipitation kinase assay using
kinase-dead MAPK as a terminal phosphoacceptor. Reaction products
were separated by SDS-PAGE, visualized by autoradiography, and
analyzed on a Molecular Dynamics PhosphorImager. The average fold
activations and S.D. values from three independent experiments are
shown. E, cells were transfected with plasmid encoding Raf-R89L,
grown to confluence, serum-starved overnight, and then incubated in
suspension for 1 h in the presence of 0.1% (v/v) Me2SO or 2.5 mM bisin-
dolylmaleimide as indicated. Cells were plated onto Fn-coated dishes and
harvested at the indicated times for analysis of Raf activity by linked
kinase assay with kinase-dead MAPK described above. The results shown
are representative of three separate transfection experiments.
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contribute to prolonged or sustained activity. This conclusion
must be tempered by the consideration that, although we used
well known PKC inhibitors, it remains possible that these drugs
affect another enzymatic activity that is involved in the process
under study. Future pursuit of this issue will entail identification
of the PKC isoform(s) putatively involved in Raf regulation.
If integrin-mediated activation of Raf does indeed comprise
an initial membrane localization phase and a later, sustained
phase governed by PKC, then compromising membrane local-
ization of Raf while inhibiting PKC activity should conspire to
completely abrogate integrin-mediated Raf activation. To test
this hypothesis, we treated Raf-R89L-transfected cells with
either solvent or PKC inhibitor and then assayed the activity of
the tagged kinase at various time points after adhesion to Fn
(Fig. 4E). As demonstrated previously in Fig. 3, Raf-R89L ac-
tivity, in the absence of PKC inhibitor, is slightly increased
early after attachment and then peaks and persists at later
time points. After treatment with BIM, however, attachment to
Fn fails to stimulate Raf-R89L activity above the level in non-
adherent cells over the entire course of the experiment.
DISCUSSION
Activation of the MAPK cascade in response to integrin-
mediated cell adhesion has been described by a number of
laboratories and in a number of cell types (for a review, see Ref.
3). Understanding the pathways that connect integrins and Raf
is fundamental to understanding the activation of the MAPK
pathway by adhesion. However, since the exact mechanism of
Raf activation in response to mitogens remains unresolved, the
mechanism of integrin-mediated Raf activation is likely to also
be somewhat elusive.
In an attempt to further define this mechanism, several
groups have defined certain factors as either requisite or dis-
pensable for integrin-mediated activation of the MAPK cas-
cade, often with conflicting results. For example, there is good
experimental evidence that suggests integrin-mediated MAPK
activation involves pp125FAK (18), Ras (18, 19), and phosphati-
dylinositol 3-kinase (17), but there is also substantial evidence
for mechanisms that are independent of pp125FAK (21, 23), Ras
(7), and phosphatidylinositol 3-kinase (22). In many of the
studies in which inhibitors of various activities were used, the
effects of these inhibitors were measured at a single time point
(usually corresponding to the peak of activity) or at a narrow
range of time points that did not encompass the full period of
MAPK activation. The results of the current study demonstrate
that initial and sustained phases of integrin-mediated activa-
tion of the MAPK cascade are governed by distinct biochemical
mechanisms. Specifically, the initial phase of activation, i.e. the
relatively high level of activity observed early after adhesion to
fibronectin, is not affected by PKC inhibitors but requires effi-
cient translocation of Raf-1 to the plasma membrane. This
translocation can be provided by interaction with Ras or by
constitutive localization by CAAX-directed prenylation. In con-
trast, the sustained phase of activation, i.e. the submaximal
activity that persists for tens of minutes up to hours, is inde-
pendent of Ras-Raf association, is blocked by PKC inhibitors,
and is lengthened by constitutive membrane localization of Raf.
The profile of Raf-R89L activation implicates Ras-Raf inter-
action as important for the initial phase but not necessarily the
later sustained phase of integrin-mediated Raf activation. At
first glance, the current results are seemingly at odds with a
previous report from our laboratory in which inhibition of Ras
function by expression of dominant negative Ras or disruption
of Ras-effector interactions by expression of the amino termi-
nus of Raf did not affect integrin-mediated MEK activation (7).
The time course analysis of the current study provides a rela-
tively straightforward explanation for this apparent discrep-
ancy. As shown in Fig. 3, the adhesion-induced activities of
Raf-WT and Raf-R89L are equivalent at 30–40 min after plat-
ing. In our previous study, measurements to determine Ras
independence were also made at 30 min after plating. Thus, it
is reasonable to expect that partial inhibition of Ras by expres-
sion of a dominant negative would have only a slight effect on
integrin-mediated activation of the MAPK pathway at this
time point. Indeed, our current results suggest that the effect of
inhibiting Ras might vary along the time course of integrin-
mediated activation of the MAPK pathway. An important ca-
veat is that in the current studies, only direct Raf-Ras interac-
tion was blocked; the function of endogenous Ras was not
perturbed. This contrasts with other studies (18, 19) using
dominant negative alleles where presumably all effectors
downstream of Ras were blocked. These effectors may influence
integrin-mediated Raf and subsequent MAPK activation in
indirect ways. In this manner, a high level of expression of a
Ras dominant negative may affect integrin-mediated activa-
tion of the Raf/MEK/MAPK pathway by both direct (e.g. dis-
ruption of Ras-Raf interaction) and indirect (e.g. inhibition of
other Ras effectors) means. In light of the current findings, it
appears clear that Ras does contribute to the initial phase of
activation of the MAPK pathway by cell adhesion. However, it
is also clear that other factors, such as PKC and cytoskeletal
elements (see below), influence the process at later times.
There is now substantial evidence that suggests an involve-
ment of integrin- or cytoskeleton-associated structures in Raf
activation. It has been established that activation of Raf by
soluble mitogens results in its translocation to the plasma
membrane and that this translocation is indeed important for
Raf activation (25, 28, 36, 37). Our laboratory has previously
shown that integrin-mediated adhesion is required for activa-
tion of Raf by mitogens (38). Furthermore, activated Raf exists
in a large multiprotein complex that is associated with the
plasma membrane and/or cytoskeleton (37). Although these
observations concern activation of Raf by soluble mitogenic
factors, it has now been established that integrin-mediated cell
adhesion to insoluble matrix proteins also activates Raf (Refs.
17 and 39; this study) and can recruit Raf into integrin-associ-
ated complexes (12). In the current study, we show that inte-
grin-mediated activation of wild-type and mutant Raf proteins
was inhibited by treatment of the cells with cytoD, demonstrat-
ing that organization of the actin cytoskeleton is important for
adhesion-mediated Raf activation. This supports earlier obser-
vations made by several groups that cytoD blocks integrin-
mediated MAPK activation (8, 9, 11, 12, 40). Disruption of actin
filament assembly may block a membrane-proximal signaling
event that is downstream of integrin engagement and cytoskel-
eton organization but is required for Raf activation. The exact
factors that mediate activation of membrane-bound Raf have
yet to be identified, but candidates include tyrosine kinases
(e.g. Src, Lck) (25, 41–43), various PKC isoforms (e.g. a, d, e,
and z) (33, 35, 44), and phospholipids (e.g. phosphatidic acid
and phosphatidylserine) (45, 46). Alternatively, disruption of
actin filament assembly may preclude the formation of a higher
order cellular structure to which Raf is recruited for activation.
This latter scenario is particularly intriguing, considering the
inhibition by cytoD of R89L-CAAX-Raf, which permanently
resides in the membrane. However, these hypotheses are cer-
tainly not mutually exclusive.
The efficient initial activation of Raf-R89L-CAAX demon-
strates that the role of Ras-Raf interaction in integrin-medi-
ated Raf activation is to target Raf to the membrane. The
regulation by adhesion of Raf-R89L-CAAX is an intriguing
observation for a number of reasons. As mentioned before,
activation of Raf involves membrane translocation and deposi-
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tion into a putatively cytoskeleton-associated cellular compart-
ment. The low level of activity of Raf-R89L-CAAX in suspen-
sion implies that the membrane-associated Raf-activating
factors are not functional in nonadherent cells but become
functional upon cell adhesion. This suggests that integrin-me-
diated cell adhesion regulates the unknown, membrane-asso-
ciated machinery responsible for activating Raf after its local-
ization to the membrane, either by activating a component(s) of
the machinery or by allowing efficient localization of these
components.
The activity of Raf-R89L-CAAX is down-regulated far more
slowly than Raf-WT, enduring at nearly maximum levels for at
least 2 h. This demonstrates an important difference in the
regulation of Raf targeted to the membrane by protein preny-
lation versus Raf targeted by more “natural” means, i.e.
through interaction with Ras. One possible explanation is that
the specific locations within the membrane to which Raf is
targeted by Ras and by CAAX-directed prenylation may be
different, and the Raf-activating factor(s) present in each may
be quantitatively or qualitatively different. Another possibility
is that inactivation of Raf after adhesion is the result of “dif-
fusion” of Raf away from membrane-bound activating factors
rather than an inactivation of the factors themselves. Thus,
Raf-R89L-CAAX, which is unable to leave the membrane, stays
active longer than Raf-WT.
Our data would suggest that PKC is not part of the machin-
ery responsible for the initial, acute activation of Raf but that
it may be involved in the subsequent maintenance of Raf ac-
tivity. Raf is directly phosphorylated and activated by PKC
(31–33), and PKC activity can be stimulated by integrin-medi-
ated cell adhesion (47). Many reports have demonstrated that
PKC-mediated activation of Raf can occur independently of Ras
(33–35, 48, 49) and therefore independently of Ras-mediated
membrane localization. This suggests that either PKC can
activate Raf in the absence of membrane translocation or that
there exists a mechanism for translocation that does not in-
volve Ras. In this regard, it is interesting to note that Raf and
PKC have been shown to form a stable complex in vivo (34, 50),
and this may serve to recruit Raf to the plasma membrane.
Interestingly, there is increasing evidence that demonstrates
direct regulation of PKC activity by aggregated syndecan-4 (51,
52). Syndecan-4 is a transmembrane heparan sulfate proteogly-
can that acts with integrins as a co-receptor for ECM ligands and
plays a critical role in the formation of focal adhesions and actin
stress fibers (53). It would be intriguing to investigate whether
integrins and syndecans coordinately regulate different phases
of the signaling pathways initiated by adhesion to Fn.
In summary, integrin-mediated activation of the Raf/MEK/
MAPK cascade appears to comprise an initial PKC-independ-
ent phase that is optimized by translocation of Raf to the
plasma membrane, followed by a sustained phase that is
blocked by PKC inhibitors. We have also shown that the activ-
ity of a constitutively membrane-associated mutant of Raf can
be regulated by integrin-mediated adhesion. Since activated
Raf exists as part of a membrane- and cytoskeleton-associated
complex, this regulation suggests that integrins may play an
important role in controlling the activation or localization of
membrane-associated factor(s) responsible for Raf activation.
In addition to its role in direct adhesion-mediated signaling,
adhesion-dependent regulation of the Raf activation machinery
may also be involved in the adhesion-dependent activation of
the MAPK cascade by growth factors (38, 52). Future studies
will be directed toward defining in more detail the adhesion-
dependent regulation of Raf proteins targeted to the mem-
brane, examining adhesion-induced changes in Raf subcellular
localization, and determining the integrin-regulated mem-
brane components or structures that influence Raf activity.
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